Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Safety Information

SML4094

RECTAS

new

≥98% (HPLC)

Synonym(s):

2-Chloro-6-Furfurylaminopurine, 2-Chloro-N-(2-furanylmethyl)-7H-purin-6-amine, 2-Chloro-N-(2-furanylmethyl)-9H-purin-6-amine, 2-Chloro-N-[(furan-2-yl)methyl]-7H-purin-6-amine, 2-Chloro-N6-furfuryl-adenine, NSC 45794, NSC-45794, NSC45794

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H8ClN5O
CAS Number:
101862-47-9
Molecular Weight:
249.66
MDL number:
MFCD09792860
UNSPSC Code:
12352200

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

SMILES string

Clc1nc2[nH]cnc2c(n1)NCc3[o]ccc3

InChI

1S/C10H8ClN5O/c11-10-15-8(7-9(16-10)14-5-13-7)12-4-6-2-1-3-17-6/h1-3,5H,4H2,(H2,12,13,14,15,16)

InChI key

QGUOPVCOXHVPJX-UHFFFAOYSA-N

Biochem/physiol Actions

Orally active, CDC2-like kinase 1 (CLK1) allosteric activator that enhances promotes CLK1/SRSF5 pathway-mediated pre-mRNA splicing events.
RECTAS is an orally active, CDC2-like kinase 1 (CLK1) allosteric activator that enhances SRSF6 c-terminal RS domain phosphorylation by CLK1, thereby promoting CLK1/SRSF5 pathway-mediated pre-mRNA splicing events. RECTAS restores IKBKAP-familial dysautonomia (FD) exon 20 inclusion in cultured cells (2-10 μM; FD patient iPSC-SNs & murine neuro 2A cells) and in IKBKAP-FD transgenic mice in vivo (two p.o. doses of 300 or 400 mg/kg 4h apart). RECTAS suppresses MC38 tumor growth (by 37/47% at 10/25 μM at the end of 33-day treatment via daily intratumoral injection) by reducing aberrant splicing events and enhancing the splice-neoantigens production.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000396621
0000396619
0000396621
0000396619

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Shingo Matsushima et al.
Science translational medicine, 14(673), eabn6056-eabn6056 (2022-12-01)
Neoantigen production is a determinant of cancer immunotherapy. However, the expansion of neoantigen abundance for cancer therapeutics is technically challenging. Here, we report that the synthetic compound RECTAS can induce the production of splice-neoantigens that could be used to boost
Specificity, synergy, and mechanisms of splice-modifying drugs
Nature Communications, 15(1), 1880-1880 (2024)
Masahiko Ajiro et al.
Nature communications, 12(1), 4507-4507 (2021-07-25)
Approximately half of genetic disease-associated mutations cause aberrant splicing. However, a widely applicable therapeutic strategy to splicing diseases is yet to be developed. Here, we analyze the mechanism whereby IKBKAP-familial dysautonomia (FD) exon 20 inclusion is specifically promoted by a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service